On Wednesday, SunTrust Banks, Inc. (NYSE:STI)’s shares declined -0.95% to $43.88.
SunTrust Banks, Inc. (STI) declared recently that it plans to release second quarter 2015 results prior to the market opening on Friday, July 17, 2015. SunTrust administration will host a conference call that morning.
SunTrust Banks, Inc. operates as the holding company for SunTrust Bank that provides various financial services in the United States. The company operates in three segments: Consumer Banking and Private Wealth Administration, Wholesale Banking, and Mortgage Banking.
Lowe’s Companies, Inc. (NYSE:LOW)’s shares gained 0.39% to $69.67.
Lowe’s Companies, Inc. (LOW) declares that Robert F. Hull, Jr., chief financial officer, and Michael P. McDermott, chief merchandising officer, will present at the Oppenheimer 15th Annual Consumer Conference in Boston, MA.
What:
Presentation by Bob Hull and Mike McDermott at the Oppenheimer 15th Annual Consumer Conference in Boston, MA
When:
9:45 a.m. Eastern Time on Wednesday, June 24, 2015
Lowe’s Companies, Inc. operates as a home improvement retailer. The company offers products for maintenance, repair, remodeling, and home decorating. It provides home improvement products under the categories of kitchens and appliances; lumber and building materials; tools and hardware; fashion fixtures; rough plumbing and electrical; lawn and garden; seasonal living; paint; home fashions; storage and cleaning; flooring; millwork; and outdoor power equipment. The company also offers installation services through independent contractors in various product categories; extended protection plans; and in-warranty and out-of-warranty repair services. It provides national brand-name merchandise and private branded products.
At the end of Wednesday’s trade, CIGNA Corporation (NYSE:CI)‘s shares surged 0.93% to $155.40.
Global health service company CIGNA Corporation (CI) has thrown in the kitchen sink for its Coach by Cigna mobile app to improve your health and well-being.
Cigna has added a new two week Hydration program to the Coach by Cigna health and fitness app, which is accessible at no charge in the Google Play™ app store for Samsung Galaxy S6 and S6 Edge and for Galaxy S5, Galaxy Note 4 and Note Edge mobile devices that have the Lollipop operating system.
The new two-week program was created by Coach Kristen Seymour, the Editor of FitBottomedGirls.com, who will assist you track your overall beverage intake, learn what proper hydration looks like, find new and healthier ways to properly hydrate and track your energy levels.
Cigna Corporation, a health services organization, provides insurance and related products and services in the United States and internationally. The company’s Commercial segment offers insured and self-insured customers medical, dental, behavioral health, and vision, in addition to prescription drug benefit plans, health advocacy programs, and other products and services. Its Government segment offers Medicare Advantage plans to seniors in 16 states and the District of Columbia, Medicare Part D plans in 50 states and the District of Columbia, and Medicaid plans.
CorMedix Inc. (NYSEMKT:CRMD), ended its Wednesday’s trading session with 6.93% gain, and closed at $5.09.
CorMedix Inc. (CRMD) declared that the U.S. Food and Drug Administration (FDA) has offered positive feedback regarding a second pivotal clinical trial protocol. The new Phase 3 protocol is designed to assess the use of Neutrolin® as a catheter lock solution in oncology patients who require total parenteral nutrition (TPN) to support filing of a New Drug Application with the FDA. The comments offered by the FDA should enhance the quality of the projected study.
Neutrolin has shown antimicrobial activity against many of the pathogens that result in catheter related bloodstream infections in the oncology community. Infections pose a noteworthyrisk for oncology patients, many of whom require the long-term use of central venous catheters. CorMedix hopes that the use of Neutrolin in this susceptible population will assist address a critical unmet medical need. Formerly, the FDA reviewed the pivotal Phase 3 clinical trial protocol to evaluate the use of Neutrolin in hemodialysis patients, and preparations are underway to initiate the trial subject to identification of funding or planned partnering.
CorMedix Inc., a pharmaceutical company, intends to in-license, develop, and commercialize therapeutic products for the prevention and treatment of cardiac, renal, and infectious diseases. The company markets Neutrolin, a catheter lock solution for the prevention of catheter related bloodstream infections and maintenance of catheter patency in tunneled, cuffed, and central venous catheters used for vascular access in hemodialysis patients.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.